Transcriptomics and Proteomics Identify Serotonin Transporter as a Promising Therapeutic Target for Essential Tremor

Essential tremor (ET) stands as one of the most prevalent movement disorders originating from cerebellar dysfunction. However, effective treatment remains limited, largely due to a poor understanding of its molecular pathology. The harmaline-induced tremor in mice is a well-established model for ET research, though its mechanisms remain unclear. This study aimed to get insight into the molecular intricacies underlying cerebellar dysfunction in this model. Combining LC-MS/MS and RNA-Seq approach, we delved into the cerebellar alterations in harmaline-induced tremor in mouse. Multi-omics profiling identified 5194 correlated coding molecules, among which 19 were significantly dysregulated. Further KEGG enrichment analysis identified cerebellar serotonin transporter (SERT) as the key molecule in harmaline-induced tremor. We validated the upregulation of SERT in the cerebellar cortex following harmaline induction, particularly within Purkinje cells, and demonstrated that pharmacological inhibition or genetical knockdown of SERT significantly attenuated tremor severity and neuronal hyperexcitability. Further mechanistic studies revealed that harmaline-induced SERT upregulation leads to depleted serotonin levels in the cerebellum, contributing to tremor pathogenesis. In general, our study unveils crucial insights that could pave the way for molecular target identification and effective therapeutic interventions for ET.